Open Access

REVIEW

ALEX A. FRANCOEUR^*, NATALIE AYOUB, DANIELLE GREENBERG, KRISHNANSU S. TEWARI
Oncology Research, Vol.33, No.7, pp. 1511-1530, 2025, DOI:10.32604/or.2025.061120 - 26 June 2025
Abstract Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy. More >

View

954

Download

542

Open Access

REVIEW

RAQUEL GÓMEZ-MOLINA^1,*, RAQUEL MARTÍNEZ^2,3,4, MIGUEL SUÁREZ^2,3,4,*, ANA PEÑA-CABIA¹, MARíA CONCEPCIóN CALDERÓN¹, JORGE MATEO^3,4
Oncology Research, Vol.33, No.7, pp. 1531-1545, 2025, DOI:10.32604/or.2025.063951 - 26 June 2025
Abstract Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer (HNPCC), is an inherited condition associated with a higher risk of colorectal cancer (CRC) and other cancers. It is caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6 and PMS2. These mutations lead to microsatellite instability (MSI) and defective DNA repair mechanisms, resulting in increased cancer risk. Early detection of LS is crucial for effective management and cancer prevention. Endoscopic surveillance, particularly regular colonoscopy, is recommended for individuals with LS to detect CRC at early stages. Additionally, universal screening of CRC for More >

Graphic Abstract

View

658

Download

320

Open Access

REVIEW

HAFIZ MUHAMMAD REHMAN^1,2,*, SIDRA AHMAD², AZEEM SARWAR¹, HAMID BASHIR^2,*
Oncology Research, Vol.33, No.7, pp. 1547-1570, 2025, DOI:10.32604/or.2025.062197 - 26 June 2025
（This article belongs to the Special Issue: Advances in Cancer Pharmacology)
Abstract Targeted cancer therapy has emerged as a promising alternative to conventional chemotherapy, which is often plagued by poor selectivity, off-target effects, and drug resistance. Among the various targeting agents in development, peptides stand out for their unique advantages, including minimal immunogenicity, high tissue penetration, and ease of modification. Their small size, specificity, and flexibility allow them to target cancer cells while minimizing damage to healthy tissue selectively. Peptide-based therapies have shown great potential in enhancing the efficacy of drug delivery, improving tumor imaging, and reducing adverse effects. With cancer responsible for millions of deaths worldwide,… More >

View

668

Download

361

Open Access

REVIEW

JIANG ZHU^*
Oncology Research, Vol.33, No.7, pp. 1571-1580, 2025, DOI:10.32604/or.2025.058957 - 26 June 2025
（This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
Abstract Changes in the intestinal immune micro-environment of the gastrointestinal tract are indispensable in the occurrence and development of gastrointestinal cancer. Tertiary lymphoid structure (TLS) is an immune cell aggregation structure found around gastrointestinal cancer in recent years. More and more research proves that tertiary lymphoid structure plays a key biological role and clinical value in disease progression, patient prognosis, and adjuvant treatment. This review aims to explore the research progress, biological significance, and potential clinical applications of TLSs in gastrointestinal tumors. The formation, development, and interaction of TLSs with tumor microenvironment have been reviewed and More >

View

700

Download

257

Open Access

REVIEW

JIAJIA LV, XIAOYOU ZHONG, LIN WANG, WEIFEI FAN^*
Oncology Research, Vol.33, No.7, pp. 1581-1592, 2025, DOI:10.32604/or.2025.060063 - 26 June 2025
（This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
Abstract The tumor microenvironment (TME) is a complex and dynamic network comprised of tumor cells, surrounding cellular components, various signaling molecules, and the stroma. Myeloid-derived suppressor cells (MDSCs) are pivotal players in the immunosuppressive landscape of the TME, effectively hindering antitumor immune responses and facilitating tumor progression. Originating from pathologically activated myeloid precursors and relatively immature myeloid cells, MDSCs retain plasticity to further differentiate into other myeloid cells, such as macrophages or dendritic cells, which underpins their heterogeneity and adaptability in response to the TME. In this review, we delve into the plasticity of MDSCs in More >

View

653

Download

224

Open Access

REVIEW

YUYU YE, YING LIU^*
Oncology Research, Vol.33, No.7, pp. 1593-1610, 2025, DOI:10.32604/or.2025.061857 - 26 June 2025
Abstract Liver cancer is the fifth most common cancer in the world, with China bearing a disproportionate burden of cases. Typically diagnosed at advanced stages, liver cancer often utilizes surgical treatments such as resection, transcatheter hepatic artery chemoembolization (TACE), and radiofrequency ablation. However, advancements in genetic engineering and tumor immunology have unveiled the distinct potential of targeted oncolytic virus therapy. Oncolytic virus, in particular, can selectively destroy tumor cells without harming normal cells, offering a promising avenue for liver cancer treatment through immune system activation, tumor microenvironment modulation, and other mechanisms. This review describes the mechanism More >

View

878

Download

505

Open Access

REVIEW

MD. MAHMUDUL HASAN^1,2, SHAH MD. WASIN^2,3, MISHU RAHMAN^2,4, EVA AZME^1,2, MD. SAQLINE MOSTAQ⁵, MD. MAHEDI HASAN NAHID⁶, NOR MOHAMMAD⁷, FARJANA AFRIN TANJUM⁸, MD. ANAMUL HAQUE⁵, MD ASHIQ MAHMUD^5,*, MOHAMMAD NURUL AMIN^5,*
Oncology Research, Vol.33, No.7, pp. 1611-1632, 2025, DOI:10.32604/or.2025.062778 - 26 June 2025
（This article belongs to the Special Issue: Breast Cancer Biomarkers and Drug Targets Discoveries Towards a More Personalized Treatment Setting)
Abstract Background: Breast cancer still stands to be the foremost contributor to cancer-related incidence and mortality in women globally accounting for about 14% of all female cancer-related deaths worldwide. This research seeks to illustrate the mechanisms and clinical findings of natural products against breast cancer treatment. Methodology: Required data for this review article was retrieved employing several readily obtainable search databases, including Web of Science^® (Thomson Reuters, USA), PubMed^® (U.S. National Library of Medicine, USA), and SciVerse Scopus^® (Elsevier Properties S.A., USA), taking into consideration certain search terms like “breast cancer,” “natural products against breast cancer,” and “Clinically… More >

Graphic Abstract

View

817

Download

326

Open Access

ARTICLE

CHENG CHENG^1,2,3, CHAO SHI^1,2, SHANG WU^1,2, WEIXING WU³, JINGPING LI^1,2, SINUO GAO^1,2, MENG HAN³, YIMIN WANG³, XIANGMEI ZHANG^2,4,*, YUNJIANG LIU^1,2,*
Oncology Research, Vol.33, No.7, pp. 1633-1648, 2025, DOI:10.32604/or.2025.061637 - 26 June 2025
（This article belongs to the Special Issue: Breast Cancer Biomarkers and Drug Targets Discoveries Towards a More Personalized Treatment Setting)
Abstract Objectives: While programmed cell death 1 (PD-1) inhibitors have improved cancer treatment, the function and mechanisms of programmed cell death ligand 1 (PD-L1), particularly when expressed by cancer cells, remain unclear. This study aims to explore the role of PD-L1 within breast cancer cells and identify key targets for future immunotherapy. Methods: RNA-seq was performed on breast cancer cells with silenced PD-L1 to screen for differentially expressed genes, followed by bioinformatics analysis. Clinical specimens from breast cancer patients undergoing primary surgery without preoperative treatment were collected, along with in vitro analysis to validate the potential mechanism. Results:… More >

View

672

Download

363

Open Access

ARTICLE

LINGJIE XU¹, YIQIN XIA¹, QIN QIN¹, GUIQUN WANG¹, KAI TAO², WEI WEI^1,*
Oncology Research, Vol.33, No.7, pp. 1649-1666, 2025, DOI:10.32604/or.2025.056176 - 26 June 2025
（This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
Abstract Background: The centrosome, a crucial cellular structure involved in the mitotic process of eukaryotic cells, plays a significant role in tumor progression by regulating the growth and differentiation of neoplastic cells. This makes the centrosome a promising target for therapeutic strategies in cancer treatment. Methods: Utilizing data from the TCGA database, we identified centrosome-related genes and constructed a prognostic model for 518 lung adenocarcinoma patients. Prognosis-associated genes were initially screened using univariate Cox regression, with overfitting minimized by applying LASSO regression to remove collinearity. Finally, a set of 12 genes was selected through multivariable Cox… More >

View

844

Download

361

Open Access

ARTICLE

KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN
Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025
（This article belongs to the Special Issue: Diagnosis and Treatment of Malignant Tumors of the Chest)
Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

View

1226

Download

406

Open Access

ARTICLE

Yanxi Peng¹, Honggen Yuan¹, Zhanjie Jiang², Xiaoqing Ou², Qian Zhang³, Kexin Yi¹, Yanbin Meng², Qun Xie^1,*
Oncology Research, Vol.33, No.7, pp. 1679-1693, 2025, DOI:10.32604/or.2025.062747 - 26 June 2025
Abstract Background: Expression of mRNA is widely regulated by N6-methyladenosine (m⁶A). An increasing number of studies have shown that m⁶A methylation, facilitated by methyltransferase 3 (METTL3), is crucial in the progression of tumors. Previous reports have indicated the involvement of both METTL3 and c-Src kinase in the evolution of liver cancer. However, the potential connection between c-Src and the METTL3-mediated mechanism in liver cancer progression remains elusive. Methods: The correlation expression between c-Src and METTL3 between liver cancer patients and the control group was analyzed using the TCGA database, and was further demonstrated by Western blot and… More >

View

385

Download

268

Open Access

ARTICLE

YOUYANG HU^1,#, YISHU LUO^1,#, TIANYUE XIE¹, YUEHUA CHEN^1,2, JUN ZHAO¹, WEICHAO JI³, ZHIWEI YAN³, SITONG QIU³, KEXIN GAO³, HAIXIA ZHU⁴, LIMIN MA^1,*, QIYOU YIN^1,*
Oncology Research, Vol.33, No.7, pp. 1695-1708, 2025, DOI:10.32604/or.2025.060021 - 26 June 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Objective: Neuroblastoma (NB) is frequently associated with high-risk pediatric cases that demonstrate limited response to cisplatin, contributing to a poor prognosis. Recent studies have explored the role of tumor cell senescence in increasing sensitivity to this chemotherapy agent. This study aims to identify genes related to cell senescence in children diagnosed with NB, evaluate their influence on cisplatin sensitivity, and investigate potential strategies to enhance the efficacy of chemotherapy. Methods: Gene expression profiles and clinical data were obtained for 498 NB patients from the GEO database (GSE49710). The study focused on identifying genes that were… More >

View

818

Download

442

Open Access

ARTICLE

KEFAN LIU¹, XIAOSONG WANG¹, XIN YANG¹, BOWEN SHI¹, LEI XING^2,*, JUNXIA CHEN^1,*
Oncology Research, Vol.33, No.7, pp. 1709-1722, 2025, DOI:10.32604/or.2025.061721 - 26 June 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Background: Accumulating studies have shown the important role of circular RNAs (circRNAs) in the oncogenesis and metastasis of various cancers. We previously reported that circACTN4 could bind with FUBP1 to promote tumorigenesis and the development of breast cancer (BC) by increasing the expression of MYC. However, its exact molecular mechanism and biological function have not been fully elucidated. Methods: Here, Circular RNA microarray analysis was conducted in 3 pairs of BC and paracancerous tissues. The expression of circACTN4 in BC cells and tissues was detected via reverse transcription‒quantitative PCR (RT‒qPCR). Cell Counting Kit-8 (CCK-8), 5-ethynyl-2-deoxyuridine… More >

Graphic Abstract

View

776

Download

332

Open Access

ARTICLE

FANGFANG HU¹, ZHIBIN BAI², YANG WANG¹, HAODONG TANG³, JIAHUA ZHOU^1,*
Oncology Research, Vol.33, No.7, pp. 1723-1737, 2025, DOI:10.32604/or.2025.059631 - 26 June 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Background: Kinesin-14 family protein 1 (KIFC1) is abnormally overexpressed in various cancers, and the transcription factor ETS variant 1 (ETV1) is an oncogenic transcription factor in tumors. The potential binding sites on the KIFC1 promoter by ETV1 were observed; however, no evidence supports that ETV1 targets KIFC1. Aims: This study aimed to investigate the relationship between KIFC1 and ETV1, and their effects and mechanisms in pancreatic cancer. Methods: Pan-cancer analysis of KIFC1 expression was performed in GEPIA2 database. KIFC1 expression levels were determined by immunohistochemistry (IHC) in our pancreatic cancer cohort. The correlation between KIFC1… More >

View

896

Download

330

Open Access

ARTICLE

JI ZENG^1,2,3,#, XUETENG MENG^1,3,#, YUAN ZHANG^1,3, JUN LI¹, TAOTAO MA^1,3,4, CHENG HUANG^1,3,*
Oncology Research, Vol.33, No.7, pp. 1739-1755, 2025, DOI:10.32604/or.2025.061978 - 26 June 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Background: Renal cell carcinoma (RCC) is a prevalent malignancy characterized by a rising incidence and significant mortality. Interleukins (ILs) are crucial in regulating immune cell trafficking and exhibit anti-tumor properties. However, limited research has explored the expression levels and prognostic significance of interleukins in RCC. Methods: In this comprehensive study, we performed a detailed analysis of interleukins in RCC patients using multiple bioinformatics tools, including Oncomine, UALCAN, GEPIA, Kaplan-Meier plotter, cBioPortal, GeneMANIA, TRRUST, STRING, and Linked Omics. Results: Our analysis demonstrated a significant upregulation in the transcriptional levels of IL4, IL7, IL15, IL16, IL23A, IL26, and… More >

View

677

Download

373

Open Access

ARTICLE

QIAN LI^1,#, SHUNPENG ZHU^1,#, MINGXIAN ZHU², FANG WANG^1,*, JINHUA ZHOU^1,*
Oncology Research, Vol.33, No.7, pp. 1757-1767, 2025, DOI:10.32604/or.2025.062539 - 26 June 2025
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Objectives: Our previous research demonstrated that SIC-19, an innovative inhibitor of salt-inducible kinase 2 (SIK2), effectively reduces SIK2 protein levels through the ubiquitin-proteasome pathway and exhibits synthetic lethal effects with poly ADP-ribose polymerase (PARP) inhibitors in ovarian cancer. However, the role of SIC-19 in triple-negative breast cancer (TNBC) and pancreatic cancer (PC) remains poorly defined. This study aims to investigate whether SIC-19 combined with PARP inhibitors can induce synthetic lethal effects in TNBC and PC. Methods: Cell lines with high SIK2 expression were identified through Western blot analysis. The combination’s impact was evaluated using Cell… More >

View

668

Download

312

Open Access

ARTICLE

KOSEI NAKAJIMA^1,2,3,*, YOSHINORI INO¹
Oncology Research, Vol.33, No.7, pp. 1769-1779, 2025, DOI:10.32604/or.2025.063419 - 26 June 2025
（This article belongs to the Special Issue: Memorial Issue to Prof. Kazuo Umezawa: A Noteworthy Biochemistry Educator)
Abstract Background: Neoadjuvant/preoperative therapy (NAT) involves the administration of chemotherapy, with or without radiation, prior to surgical resection. This approach is commonly used for locally advanced tumors to reduce tumor volume, improve resectability, and minimize the need for extensive surgical procedures. While NAT has been shown to be effective in inducing local anti-tumor immunity in potentially resectable solid tumors, the underlying molecular mechanisms remain poorly understood. Methods: Cohort samples from pancreatic cancer patients who underwent NAT (n = 26) and those who did not (n = 20) were analyzed. Changes in the immune microenvironment induced by… More >

View

383

Download

251

Open Access

ARTICLE

YA-LING YEH¹, YING-JAN WANG¹, SHOEI-YN LIN-SHIAU^2,3,*
Oncology Research, Vol.33, No.7, pp. 1781-1796, 2025, DOI:10.32604/or.2025.063717 - 26 June 2025
（This article belongs to the Special Issue: Advances in Cancer Pharmacology)
Abstract Background: The increasing incidence of cancers and infectious diseases worldwide presents a significant public health challenge that requires immediate intervention. Our strategy to tackle this issue involves the development of pharmaceutical formulations that combine phytopolyphenols (P), targeted drugs (T), and metal ions (M), collectively referred to as PTM regimens. The diverse pharmacological properties of PTM regimens are hypothesized to effectively reduce the risk factors associated with both cancers and infectious diseases. Methods: The effects of the pharmaceutical agents on the proliferation of cultured cancer cells and pathogens were assessed after 72 h and 48 h,… More >

View

294

Download

228

Open Access

CORRECTION

LICHEN XU^1,2, PAN ZHANG³, GUIQI ZHANG², ZHAOLIANG SHEN⁴, XIZHUANG BAI^1,3,*
Oncology Research, Vol.33, No.7, pp. 1797-1798, 2025, DOI:10.32604/or.2024.061279 - 26 June 2025
Abstract This article has no abstract. More >

View

196

Download

207

Open Access

CORRECTION

FANG CHEN¹, DONGQIANG YANG², YUHUA RU³, SHAN CAO¹, AISHE GAO¹
Oncology Research, Vol.33, No.7, pp. 1799-1800, 2025, DOI:10.32604/or.2025.064363 - 26 June 2025
Abstract This article has no abstract. More >

View

113

Download

83

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.33, No.7, pp. 1801-1802, 2025, DOI:10.32604/or.2025.068988 - 26 June 2025
Abstract This article has no abstract. More >

View

170

Download

105